Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

bioAffinity Technologies (BIAF) Accumulated Expenses (2022 - 2025)

Historic Accumulated Expenses for bioAffinity Technologies (BIAF) over the last 4 years, with Q3 2025 value amounting to $984547.0.

  • bioAffinity Technologies' Accumulated Expenses rose 887.97% to $984547.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $984547.0, marking a year-over-year increase of 887.97%. This contributed to the annual value of $1.4 million for FY2024, which is 2164.8% up from last year.
  • Latest data reveals that bioAffinity Technologies reported Accumulated Expenses of $984547.0 as of Q3 2025, which was up 887.97% from $1.0 million recorded in Q2 2025.
  • bioAffinity Technologies' 5-year Accumulated Expenses high stood at $1.6 million for Q3 2022, and its period low was $481336.0 during Q1 2023.
  • Its 4-year average for Accumulated Expenses is $960860.9, with a median of $969093.0 in 2024.
  • Data for bioAffinity Technologies' Accumulated Expenses shows a peak YoY increase of 11218.37% (in 2023) and a maximum YoY decrease of 5976.34% (in 2023) over the last 5 years.
  • Over the past 4 years, bioAffinity Technologies' Accumulated Expenses (Quarter) stood at $541894.0 in 2022, then soared by 112.18% to $1.1 million in 2023, then increased by 21.65% to $1.4 million in 2024, then decreased by 29.61% to $984547.0 in 2025.
  • Its Accumulated Expenses was $984547.0 in Q3 2025, compared to $1.0 million in Q2 2025 and $1.4 million in Q1 2025.